Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab.
Date
2020-01-01ICR Author
Author
Schroeder, BA
Kohli, K
O'Malley, RB
Kim, TS
Jones, RL
Pierce, RH
Pollack, SM
Type
Journal Article
Metadata
Show full item recordAbstract
Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted.
Collections
Subject
GIST
Imatinib
Metastatic
Nivolumab
PD-1
PD-L1
Refractory
Sarcoma
Wild-Type
Drug Resistance, Neoplasm
Gastrointestinal Neoplasms
Gastrointestinal Stromal Tumors
Humans
Nivolumab
Protein Kinase Inhibitors
Language
eng
Date accepted
2019-12-05
License start date
2020-01-01
Citation
OncoImmunology, 2020, 9 (1), pp. 1710064 -
Publisher
TAYLOR & FRANCIS INC